Effectiveness and Neuropsychological Predictors of Guided Self-Help for Obsessive-Compulsive Disorder (OCD)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01659125|
Recruitment Status : Completed
First Posted : August 7, 2012
Results First Posted : January 7, 2016
Last Update Posted : January 7, 2016
|Condition or disease||Intervention/treatment||Phase|
|Obsessive-Compulsive Disorder||Behavioral: "OCFighter"||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||26 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Effectiveness and Neuropsychological Predictors of Guided Self-Help for OCD|
|Study Start Date :||August 2012|
|Actual Primary Completion Date :||June 2014|
|Actual Study Completion Date :||June 2014|
OCFighter™ s an interactive, internet guided self-help (GSH) treatment program for obsessive-compulsive disorder (OCD). It uses the evidence based approach known as Cognitive Behavioral Therapy (CBT) and was adapted from the previously validated BT STEPS program for OCD. The program teaches the best practice CBT technique to help with OCD called exposure with ritual prevention (ERP).
- Change in Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) [ Time Frame: Baseline (pretreatment), 17-weeks (posttreatment), and 6 month-follow-up ]The Y-BOCS is a semi-structured interview that assesses severity of obsessions and compulsions. The total score is reported here and ranges from 0 to 40 with higher scores indicating more severe OCD symptoms.
- Responder Status [ Time Frame: Week 17 (post-treatment) and 6-month follow-up ]Participants who experienced a clinically significant change in Y-BOCS score defined as posttreatment YBOCS score that (a) has decreased by a reliable level (at least 1.96 times the standard deviation of that measure, taking into account the reliability of the measure itself; in this case, a decrease of 5 points or more), and (b) is within the nonclinical range of scores (in this case, a score of 13 or below).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01659125
|United States, Connecticut|
|Hartford, Connecticut, United States, 06106|
|Principal Investigator:||Gretchen Diefenbach, Ph.D.||Hartford Hospital|